Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz-February 2024-www.financetom.com

Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz

Jul 1, 2024 6:41 AM

09:19 AM EDT, 07/01/2024 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) said Monday that a US District Court in Delaware has allowed its patent lawsuit against Teva Pharmaceuticals USA and Apotex to proceed.

The lawsuit, which was filed in December 2022, alleges that Teva and Apotex infringed Vanda's patent related to its sleep disorder medicine Hetlioz.

Vanda said it plans to request remedies from the court including an order for Teva and Apotex to discontinue marketing their generic versions of Hetlioz.

Teva Pharmaceuticals USA is a unit of Teva Pharmaceutical Industries ( TEVA ) .

Vanda shares were up 2.1% in recent Monday premarket activity.

Price: 5.78, Change: +0.13, Percent Change: +2.30

Previous page： Davids Tea Q2 Adjusted Loss Narrows on Higher Revenue Next page： Sage Therapeutics Files Registration Statement for Planned Mixed-Shelf Offering

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Davids Tea Q2 Adjusted Loss Narrows on Higher Revenue

Sep 17, 2024

07:27 AM EDT, 09/17/2024 (MT Newswires) -- Davids Tea (DTEA.V) on Tuesday said its second-quarter adjusted loss narrowed on higher revenue. The specialty tea company said its loss adjusted for one-time items fell to $1 million, or $0.04 per share, from last year's $3.6 million, or $0.14 per share. Revenue rose 13%, to $11.1 million. Sales in Canada, which accounted...

Sage Therapeutics Files Registration Statement for Planned Mixed-Shelf Offering

Sep 17, 2024

07:22 AM EDT, 09/17/2024 (MT Newswires) -- Sage Therapeutics ( SAGE ) filed a registration statement Monday for its plan to sell and issue securities from time to time under one or more offerings and a sales agreement with TD Securities for up to $250 million of its common shares. The company said the securities to be sold can include...

Ferguson Q4 Adjusted Earnings, Revenue Advance; 2025 Sales Guidance Issued; Quarterly Dividend Maintained

Sep 17, 2024

07:19 AM EDT, 09/17/2024 (MT Newswires) -- Ferguson (FERG) reported fiscal Q4 adjusted earnings Tuesday of $2.98 per diluted share, up from $2.77 a year earlier. Analysts polled by Capital IQ expected $2.86. Net sales for the fiscal quarter ended July 31 was $7.95 billion, up from $7.84 billion a year earlier. Analysts surveyed by Capital IQ expected $8.02 billion....

Express Scripts sues FTC over drug pricing report

Sep 17, 2024

NEW YORK, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts sued the U.S. Federal Trade Commission on Tuesday over the regulator's recent drug pricing report, calling the report's conclusion that the prescription middlemen raise drug costs defamatory. The lawsuit asks a federal judge in St. Louis, Missouri to order the FTC to take the report down and recuse Chair...